Navigation Links
Harvard University: Big Pharma is Corrupted; CBCD Sees Connection between Corruption & Productivity Crisis in R&D
Date:11/1/2013

Rochester, NY (PRWEB) November 01, 2013

Big Pharma suffers from institutional corruption according to Harvard University researchers (1). They came to this conclusion after examining Pharma’s practices and policies in 5 different categories: systemic problems, medical research, medical knowledge and practice, marketing, and patient advocacy organizations. The CBCD believes this institutional corruption is a result of the productivity crisis in pharmaceutical R&D.

What is institutional corruption?

According to Marc A. Rodwin, one of the lead researchers, institutional corruption is “widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. Institutional corruption displaces some goals and compromises the attainment of others (2).”

An example of systemic corruption, (corruption of the entire system, or way of doing things) is Big Pharma’s funding of political campaigns, selectively providing information to legislators, subsidizing their work, and targeting campaign contributions to influential legislators and allies (1). Another example of a systemic problem is the fact that “Firms have strong financial incentives to develop so-called me-too drugs - products which are minor variations of existing drugs - and to heavily market them in ways that exaggerate their benefits and fail to reveal their full risks (1).”

The Harvard researchers found that Big Pharma manipulates physicians across America to achieve their financial goals. They wrote that “widespread practices in the medical and pharmaceutical industries can lead to doctors who are psychologically, financially, or intellectually dependent on drug companies (1).” In other words, Pharma turned these doctors into their agents. This is a phenomenon which has “resulted in…Doctors who take such misleading information at face value (and) prescribe drugs that are often unnecessary, harmful to patients, or more costly than equivalent medications (1).”

In short, the Harvard researchers “uncovered how pharmaceutical marketing …distorts medical practice… (1).”

When normal people become corrupted, it is usually due to extreme pressure. For example, when someone holds a gun to the head of one’s child, or when one is bankrupt and must still purchase food for one’s family…then one may be driven to extreme acts. The same holds true for Big Pharma. The productivity crisis is driving Pharma to extreme measures. These extreme measures were labeled by researchers as ‘institutional corruption.’

For more information on the productivity crisis in pharmaceutical R&D, please visit:

http://www.prweb.com/releases/2013/10/prweb11232090.htm

and

http://www.prweb.com/releases/2013/10/prweb11273236.htm

The CBCD invites pharmaceutical executives to contact the Center to discuss forward thinking strategies that can help reduce corruption while maximizing profits.

We invite the media to contact us for interviews at: info (at)buy-gene-eden(dot)com or phone 585-250-9999.

###

References:
(1)    http://www.law.harvard.edu/news/2013/10/25_edmond-j-safra-center-for-ethics-fellows-jlme.html
(2)    http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2298140
(3)    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11290033.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Harvard researchers, pharma experts offer recommendations to expand access to clinical trial data
2. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
3. Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
4. Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture
5. Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
6. Harvard Wyss Institutes Lung-on-a-Chip wins prize for potentially reducing need for animal testing
7. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
8. Harvards Wyss Institute models a human disease in an organ-on-a-chip
9. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
10. Harvards Wyss Institute creates living human gut-on-a-chip
11. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)...  Bayer today announced that a Phase III ... (regorafenib) tablets for the treatment of patients with ... endpoint of a statistically significant improvement in overall ... and safety of regorafenib in patients with HCC ... The safety and tolerability were generally consistent with ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... recent innovations in biotechnology to help treat hormonal and stress related hair loss. ... has captured the hearts of key opinion leaders in the medical and salon ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... at Boston CEO 2016 on May 31st and June 1st at The Four ... for leading executives in the life sciences, offering exclusive access to key decision ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):